Baseline characteristics
Between December 2021 and June 2023, a total of 56 unresectable NSCLCm patients in stage III were enrolled in this trial (Fig. 1). Among them, 5 patients withdrew their informed consents, leaving 51 participants who…
Neoadjuvant Aumolertinib for unresectable stage III EGFR-mutant non-small cell lung cancer: a single-arm phase II trial
